OBJECTIVES: A lifelong nature of COPD therapy requires significant costs from the patient’s budget. GOLD develops recommendations for the treatment of COPD, which correspond to the modern level of medicine and ensure proper quality of patients’ lives. The aim of this work is to identify the availability of drugs recommended by GOLD for patients in Ukraine from the perspective of physical availability of the drug in a pharmacy and in terms of its affordability.  METHODS: To determine the affordability of drugs, the paying capacity adequacy rate (Сa.s.) for 2014 was calculated. RESULTS: In the Ukrainian market, there are 18 out of 32 drugs recommended by GOLD for the treatment of stable COPD course. A group of long-acting anticholinergics (2 out of 4 drugs) and combined drugs glucocorticosteroids + β-agonists in one inhaler (2 out of 4 drugs) is presented insufficiently, and long-acting combinations of anticholinergic + β-agonists are not available in the market. According to capacity adequacy rate (Сa.s.), in 2014 a month of treatment with the studied drugs cost 0.2 % to 58.01 % of the average monthly salary of the patient. In 2014, the least affordable drugs for patients with COPD were drugs from the inhaled corticosteroids group: Flixotide nebules, Nebufluzone and Pulmicort, the cost of which varied from 19.86% to 58.01%, which can be afforded only by patients with incomes above the average. The most affordable drug is a short-acting β2-agonist– salbutamol (Ca.s. 0.43-15.70%). CONCLUSIONS: Ukraine faces a rather difficult situation for patients with COPD. Drugs recommended by GOLD are presented insufficiently, and a large number of drugs available in the market are not readily available to patients.